Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedcrizotinib
Educational only, not medical advice. OncoForge makes no claim that Crizotinib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · Sep 2018 · Case report
This is a case report of a 15-year-old girl with epithelioid inflammatory myofibroblastic sarcoma (EIMS) of the ovary harboring a RANBP2-ALK fusion. Over 2 years she experienced multiple recurrences. After the tumor was classified as EIMS, she was treated with the ALK inhibitor crizotinib and had disease improvement within weeks. The authors state this is the first reported EIMS arising in the female genital tract.
Reported effect: follow-up 2, n=1
Key findings
Patient: 15-year-old girl with ovarian EIMS harboring a RANBP2-ALK fusion.
Clinical course: multiple recurrences during 2 years of follow up.
Intervention: started treatment with an ALK inhibitor (crizotinib) after classification as EIMS.
Outcome: crizotinib led to disease improvement within weeks of administration.
Novelty: reported as the first known case of EIMS arising in the female genital tract.
Limitations: Single-patient case report (n=1).; No quantitative response metrics or imaging/biomarker data provided in abstract.; No dose, regimen, or detailed timeline of crizotinib treatment reported in abstract.; No control group or comparative data; observational..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
This paper is a review about ALK rearrangements in non-small-cell lung cancer and the drug crizotinib. It summarizes ALK fusion partners, ways to detect ALK rearrangement, and notes that many ALK fusions in NSCLC patients respond well to crizotinib. No new patient data or trial results are reported in the abstract.
Key findings
ALK rearrangements in NSCLC involve multiple fusion partners, including EML4, KIF5B, KLC1, and TPR.
The review states that most ALK fusions in NSCLC patients respond well to the ALK inhibitor crizotinib.
The paper also reviews detection methods for ALK rearrangement.
Limitations: Review article; no original experimental or clinical outcome data in the abstract.; No quantitative results, sample size, dose, or follow-up are reported.; The abstract does not specify the evidence base behind the statement that most ALK fusions respond well to crizotinib..
Background review of an actionable oncogenic alteration and its targeted inhibitor in NSCLC.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Crizotinib's evidence base, and anything that's been retracted.
Cancers where Crizotinib reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Single-patient case report (n=1).; No quantitative response metrics or imaging/biomarker data provided in abstract.; No dose, regimen, or detailed timeline of crizotinib treatment reported in abstract.; No control group or comparative data; observational..
Limitations: Single-patient case report (n=1).; No quantitative response metrics or imaging/biomarker data provided in abstract.; No dose, regimen, or detailed timeline of crizotinib treatment reported in abstract.; No control group or comparative data; observational..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
2 ongoing · 4 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.